CN107286139B - Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs - Google Patents
Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs Download PDFInfo
- Publication number
- CN107286139B CN107286139B CN201610224082.7A CN201610224082A CN107286139B CN 107286139 B CN107286139 B CN 107286139B CN 201610224082 A CN201610224082 A CN 201610224082A CN 107286139 B CN107286139 B CN 107286139B
- Authority
- CN
- China
- Prior art keywords
- compound
- deuterated
- acid addition
- addition salt
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
The invention discloses an acid addition salt of a deuterated dehydrophenylalsteine compound and application thereof in preparing an anti-tumor medicament. The invention discloses a preparation process of an acid addition salt of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione compound, and the obtained salt forming compound aims to remarkably improve the solubility and bioavailability of an active ingredient of the compound, so that the curative effect and dosage form selection of the antitumor drugs are fully embodied and applied.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and relates to an acid addition salt of a deuterated dehydrophenylalsteine compound and application thereof in preparing an anti-tumor medicament.
Background
((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuteromethylene) piperazine-2, 5-dione is dehydrophenylalstein (Plinabulin, in third-phase clinic) which is a derivative of the cyclic dipeptide Phenylthionin of marine aspergillus as a lead compound, the novel tubulin binding agent obtained by structural modification has good anti-tumor activity, and can overcome the drug resistance of paclitaxel, selectively act near the colchicine binding site of endothelial tubulin, inhibit the polymerization of the tubulin, block the formation of microtubules, stop cells at the early stage of mitosis, and further inducing cell death, inhibiting angiogenesis and blocking cancer cell supply, thereby synergistically inhibiting rapid proliferation of cancer cells, wherein the specific structural formula is as follows:
through research, the IC50 of (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione is lower than that of the analogue plinabulin, but the water solubility is poor, so that the application of the analogue in clinical medicines is severely limited. In order to improve the drug solubility and bioavailability of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-diketone, the research on the acid addition salt thereof is particularly important.
Meanwhile, a preparation method and application of the (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-diketonic acid addition salt are not reported.
Disclosure of Invention
The invention provides an acid addition salt of a deuterated dehydrophenylalsteine compound and application thereof in preparing an anti-tumor medicament.
The invention further provides application of the (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-diketonic acid addition salt in preparation of antitumor drugs.
In order to realize the purpose of the invention, the invention adopts the following technical scheme to realize:
the invention provides an acid addition salt of a deuterated dehydrophenylalsatidine compound, which has a structure shown in a general formula (II) and is formed by reacting the deuterated dehydrophenylalsatidine compound with an acid, wherein the structure shown in the general formula (I) is as follows:
r in the general formulae (I) and (II)1Is a polysubstitution group which is not equal to the primary substitution to the five substitution on the benzene ring, and the substituent is selected from hydrogen atom, deuterium atom, halogen atom, hydroxyl, methoxy group, amino group, phenyl group, aminomethyl phenyl group, benzoyl group, C1-C24 alkyl group, C2-C24 alkenyl group, C2-C24 alkynyl group, aryl alkyl group, heterocyclic aryl alkyl group, acyl group of C1-C24, alkoxy group of C1-C24, carboxyl group, carboxylic ester group, amido group, N-monosubstituted or N, N-disubstituted amido group, sulfonic groupSulfonate, sulfonamide, N-substituted sulfonamide, alkoxy, arylalkoxy, alkylthio, cyano, amino, substituted amino, nitro; cycloalkyl, cycloalkenyl, aryl, substituted aryl, aromatic heterocyclic, aryloxy, aroyl, epoxy, cycloacyl, aromatic thio, aromatic sulfonyl;
R2is a hydrogen atom or a deuterium atom;
X1is an oxygen atom or a sulfur atom, X2Is an oxygen atom or a sulfur atom;
X3is-NH, an oxygen atom or a sulfur atom;
(A)nwherein A represents acid, including inorganic acid and organic acid, wherein the inorganic acid includes hydrochloric acid, sulfuric acid, phosphoric acid; organic acids include methanesulfonic acid, trifluoroacetic acid, p-toluenesulfonic acid, oxalic acid, maleic acid, fumaric acid, acetic acid, succinic acid, citric acid, lactic acid, malic acid, tartaric acid, ascorbic acid, nicotinic acid, aliphatic or aromatic carboxylic or sulfonic acids; n represents 1/2, 1 or 2.
Further: the preparation method of the acid addition salt of the compound comprises the following steps: heating and dissolving the compound shown in the general formula (I) in an organic solvent, dropwise adding 1-2 equivalents of acid solution dissolved in the organic solvent, stirring and reacting at 0-50 ℃, separating out a solid, filtering, washing and drying to obtain the acid addition salt solid of the deuterated dehydrophenylalsteinensis compound.
Further: the organic solvent is one or more of methanol, ethanol, ethyl acetate, isopropanol, tetrahydrofuran, dichloromethane or acetone.
Further: the heating and dissolving temperature is 15-50 ℃.
Further: the acid addition salt of the deuterated dehydrophenylalsteine compound is an acid addition salt of (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-diketone. .
Further: the acid addition salts of the (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione are hydrochloride, methanesulfonate and oxalate thereof; the organic solvent is one or more of methanol, ethanol and acetone; the heating and dissolving temperature is 40-50 ℃.
Further: the ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione hydrochloride is crystalline powder, wherein the compound and the hydrochloric acid form a salt in a molar ratio of 1:1, the melting point is 290 ℃ and 291 ℃, and an absorption peak of an X-ray powder diffraction characteristic is shown in figure 1.
Further: the methane sulfonate of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione is crystalline powder, wherein the compound and the methanesulfonic acid are in a molar ratio of 1:1 to form salt, the melting point is 303-305 ℃, and the characteristic absorption peak of X-ray powder diffraction is shown in figure 2.
Further: the oxalate of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione is crystalline powder, wherein the compound and oxalic acid are in a molar ratio of 2:1 to form a salt, the melting point is 262-263 ℃, and the characteristic absorption peak of X-ray powder diffraction is shown in figure 3.
The invention also provides application of the acid addition salt of the deuterated dehydrophenylalsteine compound in preparing an anti-tumor medicament, which is characterized in that the tumor is solid tumor including non-small cell lung cancer, pancreatic cancer, skin cancer and leukemia cells.
The invention has the advantages and technical effects that: the invention provides acid addition salts of deuterated dehydrophenylalsteines, particularly a problem of low solubility of (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazole-4-yl) deuterated methylene) piperazine-2, 5-dione, and a preparation process thereof, aiming at solving the problem, the solubility of the acid addition salts of the deuterated dehydrophenylalsteines is obviously improved, which has an important significance for improving the bioavailability of active ingredients of the deuterated dehydrophenylalsteines in pharmaceutical application, and simultaneously can widen dosage form selection of the deuterated dehydrophenylalsteines in pharmaceutical application.
Drawings
FIG. 1 is an X-ray powder diffraction pattern of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione hydrochloride of the present invention.
FIG. 2 is an X-ray powder diffraction pattern of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione mesylate salt according to the invention.
FIG. 3 is an X-ray powder diffraction pattern of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuteromethylene) piperazine-2, 5-dione oxalate of the present invention.
Detailed Description
The technical solution of the present invention will be described in further detail with reference to specific examples.
Example 1
The preparation method of the deuterated dehydrophenylaspartine compound with the structure shown in the general formula (I) comprises the following steps:
(1) synthesis of deuteroaldehyde compound b: starting from the 5-tert-butyl-1H-imidazole-4-carbaldehyde via NaBD4Reducing and oxidizing manganese dioxide to obtain 5-tert-butyl-1H-imidazole-4-deuterated formaldehyde,
(2) the first step of condensation reaction: firstly, carrying out condensation reaction on diacetyl piperazinedione (DKP) and the aldehyde intermediate a or the deuteroaldehyde compound b to form a heterocyclic compound c or a deuterium-containing heterocyclic compound d;
(3) the second step of condensation reaction: then the heterocyclic compound c or the heterocyclic compound d containing deuterium and a second condensation reaction aldehyde are subjected to condensation reaction to form the deuterated dehydrophenylalstidine compound; the second condensation reaction aldehyde is benzaldehyde, deuterated benzaldehyde or benzaldehyde derivative and deuterated benzaldehyde derivative with substituent groups on benzene rings;
example 2
Preparation of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione hydrochloride
The specific preparation process comprises the following steps: dissolving ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuteromethylene) piperazine-2, 5-dione (100mg, 0.30mmol) in 3ml of acetone, adding acetone-diluted hydrochloric acid (16mg, 0.44mmol) dropwise, stirring at room temperature to react for 1.5H, filtering with suction, washing the filter cake with acetone to obtain a white solid, forming a salt with hydrochloric acid in a molar ratio of 1:1, yield 72%. m.p.290-291 ℃.,. delta.13.07 (brs,1H),11.61(brs,1H),10.19(s,1H),8.36(brs,1H),7.51(d, J ═ 7.7Hz,2H),7.41(t, J ═ 7.6Hz,2H),7.31(t, J ═ 7.3H, 1H), 7.6H ═ 7.7, 9H), the specific characteristic absorption peak is shown in figure 1 by X-ray powder diffraction test.
Example 3
Preparation of ((3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione mesylate
The specific preparation process comprises the following steps: (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuteromethylene) piperazine-2, 5-dione (200mg, 0.59mmol) was dissolved in 4ml acetone at room temperature, acetone diluted methanesulfonic acid (86mg, 0.89mmol) was added dropwise, the reaction was stirred at room temperature for 1.5H, filtered, and the cake was washed with acetone to give 229mg of a white solid, yield 89%, salt formation with methanesulfonic acid at a molar ratio of 1: 1. m.p.303-305 ℃ 1H NMR (500MHz, DMSO-d6) delta 12.92(brs,1H),11.69(brs,1H),10.20(s,1H),8.31(brs,1H),7.53(d, J ═ 7.6Hz,2H),7.43(t, J ═ 7.7Hz,2H),7.33(t, J ═ 7.3H, 1H), 7.78 (t, H ═ 7.6Hz, 1H),2.33(s,3H),1.37(s,9H), and the specific characteristic absorption peak is shown in figure 2 by X-ray powder diffraction test.
Example 4
Preparation of (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuterated methylene) piperazine-2, 5-dione oxalate
The specific preparation process comprises the following steps: (3Z,6Z) -3-benzylidene-6- ((5-tert-butyl-1H-imidazol-4-yl) deuteromethylene) piperazine-2, 5-dione (200mg, 0.59mmol) was dissolved in 4ml acetone at room temperature, oxalic acid (112mg, 0.89mmol) was slowly added, the reaction was stirred at room temperature for 1.5H, suction filtered, and the cake was washed with acetone to give 219mg of a white solid in 80% yield, which was salified with oxalic acid at a molar ratio of 2: 1. m.p.262-263 deg.C, 1H NMR (500MHz, DMSO-d6) delta 12.33(s,1H),12.23(s,1H),10.01(s,1H),7.86(s,1H),7.53(d, J ═ 7.6Hz,2H),7.42(t, J ═ 7.6Hz,2H),7.32(t, J ═ 7.4, 1H), 6.75H, s (39.75 Hz), 9H) the specific characteristic absorption peak is shown in figure 3 by X-ray powder diffraction test.
Example 5: determination of equilibrium solubility
Appropriate amount of the compound is weighed respectively and dissolved in DMSO to prepare 1mg/mL mother solution. And diluting the mother liquor with methanol to obtain different concentration points, and making a standard curve of the sample.
A1.5 mL brown EP tube was taken and 1mL ultrapure water was added. Then, an appropriate amount of the compound is respectively taken and added into a brown EP tube, vortex oscillation is carried out, and ultrasound is carried out until the medicine is not dissolved (the solution is turbid or suspended particles exist). Placing into an incubation oscillator, maintaining the temperature at 37 + -1 deg.C and 100r/min, and shaking for 24 hr to achieve full dissolution balance. After 24h, the saturated solution was removed, the supernatant was quickly filtered through a 0.45um microfiltration membrane, the primary filtrate was discarded, and the subsequent filtrate was diluted one time with methanol. Each set was prepared with 3 samples in parallel. According to the chromatographic conditions, the sample is injected, the peak area is measured and the equilibrium solubility of each compound in pure water is calculated. The test results are shown in Table 1.
Table 1 equilibrium solubility data for compounds
The experimental results in table 1 show that the solubility of the compound can be greatly improved after salification.
Example 6
The IC50 of the selected compounds on the growth of tumor cells BXPC-3 and Jurkat was determined by the MTT assay.
Experimental materials:
1) cell lines: human pancreatic cancer cell BXPC-3 and human acute T cell leukemia cell Jurkat. Cells were grown in RPMI-1640 medium and high glucose DMEM (Gibco BRL, Rockville, Md., USA) + 10% fetal bovine serum (containing 2mM L-glutamine, penicillin and streptomycin) at 37 deg.C (5% CO)2-95% air) in an incubator, digested with 0.25% trypsin and passaged 1-2 d after 1 exchange of the medium.
2) Dissolution and dilution of the compound: according to the molecular weight and the mass of the compound, DMSO (SIGMA) is respectively prepared into 10mM mother liquor, and then the mother liquor is diluted to the required concentration of 100 mu M (the DMSO content is less than or equal to 3 per mill) by RPMI-1640 culture medium. The diluted drug was stored at-20 ℃.
3) RPMI 1640 cell culture medium, Gibco; fetal bovine serum, Hyclone; cell digest, 0.25% Trypsin + 0.02% EDTA.
4) MTT solution and MTT dry powder (Sigma) are fully dissolved by PBS to prepare 5mg/ml, and are subpackaged after being filtered by a 0.22 mu m microporous filter membrane and stored at the temperature of minus 20 ℃.
The experimental steps are as follows:
1) cell inoculation: collecting cells in logarithmic growth phase, digesting with pancreatin, dispersing into single cells, counting, adjusting cell suspension to 8.0 × 104One cell/mL, 180. mu.L per well, was seeded in a 96-well plate to give a seeded cell count of 4.0X 103Per well. After the cells were attached to the wall, fresh media containing compounds at different concentrations were added to make the concentrations 100nM, 50nM, 25nM, 12.5nM, 6.25nM and 3.125nM, respectively, with 3 duplicate wells for each concentration, protected from light during the operation, and the DMSO content in each concentration was adjusted to be the same.
2) After 72h drug incubation, 20. mu.L MTT (3- [4, 5-dimethylthiozol-2-yl) was added to each well]-2,5-diphenyltetrazolium bromide, Sigma; 5mg/mL), placing in an incubator, incubating for 4h, removing supernatant, adding 150 mu LDMSO per well for dissolution, and measuring the absorbance value at 570nm by using a microplate reader. According to the formula: inhibition rate [ (A)570 control well-A570 administration hole)/A570 control well]X 100%, the inhibition ratio at each concentration was calculated and IC50 was obtained, and the results are shown in table 2.
TABLE 2 IC of Compounds on human cell lines50Value (nM)
The experimental results in table 2 show that the in vitro antitumor activity after salification is basically consistent; the activity to the mesylate salt decreased slightly.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions.
Claims (2)
1. An acid addition salt of a deuterated dehydrophenylasparteine compound,
the acid addition salt of the deuterated dehydrophenylalsteine compound is an acid addition salt of (3Z,6Z) -3-benzylidene-6- [ (5-tert-butyl-1H-imidazole-4-yl) deuterated methylene ] piperazine-2, 5-diketone;
the acid addition salts of the (3Z,6Z) -3-benzylidene-6- [ (5-tert-butyl-1H-imidazol-4-yl) deuterated methylene ] piperazine-2, 5-dione are hydrochloride, methanesulfonate and oxalate thereof;
the (3Z,6Z) -3-benzylidene-6- [ (5-tert-butyl-1H-imidazole-4-yl) deuterated methylene ] piperazine-2, 5-dione hydrochloride is crystalline powder, wherein the compound and the hydrochloric acid are in a molar ratio of 1:1 to form a salt, the melting point is 290 ℃ and 291 ℃, and an absorption peak of an X-ray powder diffraction characteristic is shown in figure 1;
the (3Z,6Z) -3-benzylidene-6- [ (5-tert-butyl-1H-imidazole-4-yl) deuterated methylene ] piperazine-2, 5-dione mesylate is crystalline powder, wherein the compound and the methanesulfonic acid are in a molar ratio of 1:1 to form a salt, the melting point is 303-305 ℃, and an absorption peak characteristic of X-ray powder diffraction is shown in figure 2;
the (3Z,6Z) -3-benzylidene-6- [ (5-tert-butyl-1H-imidazole-4-yl) deuterated methylene ] piperazine-2, 5-dione oxalate is crystalline powder, wherein the compound and oxalic acid are in a molar ratio of 2:1 to form a salt, the melting point is 262-263 ℃, and an absorption peak of an X-ray powder diffraction characteristic is shown in figure 3.
2. The use of an acid addition salt of a deuterated dehydrophenylalsteine compound as claimed in claim 1 for the preparation of a medicament against tumors, wherein said tumors are solid tumors of non-small cell lung cancer, pancreatic cancer, skin cancer and leukemia cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610224082.7A CN107286139B (en) | 2016-04-12 | 2016-04-12 | Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610224082.7A CN107286139B (en) | 2016-04-12 | 2016-04-12 | Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107286139A CN107286139A (en) | 2017-10-24 |
| CN107286139B true CN107286139B (en) | 2020-02-21 |
Family
ID=60093564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610224082.7A Active CN107286139B (en) | 2016-04-12 | 2016-04-12 | Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107286139B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018028420A1 (en) | 2016-08-12 | 2018-02-15 | 青岛海洋生物医药研究院股份有限公司 | Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof. |
| CN110835335B (en) * | 2018-08-17 | 2022-04-15 | 深圳华大海洋科技有限公司 | 2, 5-diketopiperazine compound and application thereof in preparation of anti-cancer drugs |
| WO2023274316A1 (en) * | 2021-06-29 | 2023-01-05 | 深圳华泓海洋生物医药有限公司 | Application of deuterated plinabulin in preparing drug for treating neutropenia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129527B2 (en) * | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
-
2016
- 2016-04-12 CN CN201610224082.7A patent/CN107286139B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 等排置换及其在药物分子设计中的应用;张磊等;《中国药物化学杂志》;20140630;214-230 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107286139A (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107286139B (en) | Acid addition salt of deuterated dehydrophenylalsteine compound and application of acid addition salt in preparation of antitumor drugs | |
| KR20080044841A (en) | POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR PREPARATION OF NOVEL CRYSTALLINE FORMS AS WELL AS AMORPHOUS AND FORM alpha; | |
| CN110099900B (en) | Hedgehog pathway inhibitors against Smoothened mutants | |
| JP6704422B2 (en) | Quinazoline derivative salt and method for producing the same | |
| JP5649652B2 (en) | Substituted hydrazide compounds and their applications | |
| CN106554347B (en) | EGFR kinase inhibitor and preparation method and application thereof | |
| KR20050009706A (en) | Process for the preparation of a hydrate of an anthranilic acid derivative | |
| CN114736214B (en) | Sesquiterpene derivative, pharmaceutical composition thereof, and preparation method and application thereof | |
| CN109879827B (en) | Indazole derivative and application thereof | |
| EP3950676A1 (en) | Preparation method for amide compound and application thereof in field of medicine | |
| CN107286220B (en) | 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof | |
| CN110615766B (en) | Disubstituted alpha, beta unsaturated ketone, preparation method and application thereof | |
| CN115068587A (en) | Glycopeptide compound with antiviral activity and application thereof | |
| CN117479934A (en) | HIPK2 inhibitors for the treatment of renal fibrosis | |
| CN114133390A (en) | Harmine derivative and preparation method and application thereof | |
| CN108912035B (en) | Indole amide compound with anti-tumor activity | |
| CN114276369B (en) | Preparation method and application of isobaicine analogue from ofloxacin to isobaicine analogue | |
| HUT65885A (en) | Process for preparing heterocyclyl-phenoxyalkyl-piperidinylpyridazines and pharmaceutical compositions containing them | |
| CN108707145A (en) | The quinolines of the structure containing five-ring heterocycles and its preparation and application | |
| CN110590724B (en) | 4-arylpyran derivative containing aryl urea and application thereof | |
| CN115368309A (en) | Isolongifolane dipyrazole derivative and preparation method and application thereof | |
| CN111825689B (en) | Crystal form of dihydropyrazolone compound and preparation method thereof | |
| CN114149394B (en) | Curcumene derivative and preparation and application thereof | |
| CN107033091B (en) | Piperazine derivative and preparation method and application thereof | |
| CN114591267A (en) | Nitrogen-containing derivatives of monocarbonyl curcumin, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200925 Address after: Room 403-406, 4th floor, building a11, Life Science Industrial Park, 140 Jinye Avenue, Kuiyong street, Dapeng New District, Shenzhen City, Guangdong Province Patentee after: SHENZHEN BGI OCEAN TECHNOLOGY Co.,Ltd. Address before: 266061 No. 23 East Hongkong Road, Laoshan District, Shandong, Qingdao Patentee before: MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210914 Address after: 518119 room 410, building a11, Life Science Park, No. 140, Jinye Avenue, Sanxi community, Kwai Chung street, Dapeng new area, Shenzhen, Guangdong Patentee after: Shenzhen Huahong marine biomedical Co.,Ltd. Address before: Room 403-406, 4th floor, building a11, Life Science Industrial Park, 140 Jinye Avenue, Kuiyong street, Dapeng New District, Shenzhen, Guangdong 518108 Patentee before: SHENZHEN BGI OCEAN TECHNOLOGY Co.,Ltd. |